David W Gjertson
Overview
Explore the profile of David W Gjertson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
1361
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sun Y, Sen S, Parmar R, Arakawa-Hoyt J, Cappelletti M, Rossetti M, et al.
Front Immunol
. 2025 Mar;
16:1542531.
PMID: 40028342
Introduction: Cytomegalovirus (CMV) viremia remains a major contributor to clinical complications in solid organ transplant (SOT) patients, including organ injury, morbidity and mortality. Given their critical role in antiviral defense,...
2.
Parmar R, Pickering H, Ahn R, Rossetti M, Gjertson D, Ruffin F, et al.
Front Immunol
. 2024 Jun;
15:1373553.
PMID: 38846955
Introduction: bacteremia (SAB) is a life-threatening infection particularly involving methicillin-resistant (MRSA). In contrast to resolving MRSA bacteremia (RB), persistent MRSA bacteremia (PB) blood cultures remain positive despite appropriate antibiotic treatment....
3.
Zhang Q, Locke A, Alvarez A, Cabarong M, Liv L, Alfaro B, et al.
Front Genet
. 2024 Feb;
15:1352764.
PMID: 38362203
Precise typing of human leukocyte antigens (HLA) is crucial for clinical hematopoietic stem cell and solid organ transplantations, transfusion medicine, HLA-related disease association, and drug hypersensitivity analysis. The UCLA Cell...
4.
Sosa R, Ahn R, Li F, Terry A, Qian Z, Bhat A, et al.
Hepatol Commun
. 2024 Jan;
8(1).
PMID: 38206205
Background: Ischemia-reperfusion injury (IRI) is a significant clinical concern in liver transplantation, with a key influence on short-term and long-term allograft and patient survival. Myeloid cells trigger and sustain tissue...
5.
Thaden J, Ahn R, Ruffin F, Gjertson D, Hoffmann A, Fowler Jr V, et al.
J Infect Dis
. 2023 Nov;
229(5):1535-1545.
PMID: 38001039
Background: Clinical outcomes in bacterial bloodstream infections (BSIs) are influenced by bacterial species, host immunity, and antibiotic therapy. The mechanisms by which such factors influence outcomes are poorly understood. We...
6.
Sosa R, Terry A, Ito T, Naini B, Zheng Y, Pickering H, et al.
Transplant Direct
. 2023 Oct;
9(11):e1550.
PMID: 37876917
Background: Nonalcoholic steatohepatitis (NASH) is a severe immune-mediated stage of nonalcoholic fatty liver disease that is rapidly becoming the most common etiology requiring liver transplantation (LT), with Hispanics bearing a...
7.
Moatamed N, Vahdatshariatpanahi S, Gjertson D, Sachs C, Kang Y, Ostrzega N, et al.
PLoS One
. 2023 Sep;
18(9):e0291361.
PMID: 37725629
Introduction: The expression of androgen receptor (AR) is not commonly tested or studied in uterine cancers, unlike estrogen receptor (ER) and progesterone receptor (PR) which are positive in most endometrial...
8.
Terry A, Kojima H, Sosa R, Kaldas F, Chin J, Zheng Y, et al.
Am J Transplant
. 2023 Aug;
23(12):1858-1871.
PMID: 37567451
Ischemia-reperfusion injury (IRI) during orthotopic liver transplantation (OLT) contributes to graft rejection and poor clinical outcomes. The disulfide form of high mobility group box 1 (diS-HMGB1), an intracellular protein released...
9.
Jenkins M, Tran D, Flores E, Kupferwasser D, Pickering H, Zheng Y, et al.
Front Immunol
. 2023 May;
14:1139915.
PMID: 37153624
Introduction: SARS-CoV-2 is the etiologic agent of coronavirus disease 2019 (COVID-19). Questions remain regarding correlates of risk and immune protection against COVID-19. Methods: We prospectively enrolled 200 participants with a...
10.
Samiei A, Gjertson D, Memarzadeh S, Konecny G, Moatamed N
Diagn Pathol
. 2022 Sep;
17(1):70.
PMID: 36104728
Background: Immune checkpoints including programmed death-ligand 1/programmed death-1/ (PD-L1/PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and indolaimine-2, 3-deoxygenase (IDO) have recently emerged as effective candidates for treatment against a range...